ADAMS R MARK
Known title: Chief Operating OfficerCIK: 0001808905
Associated companies
Transaction History
| ADPT | ▼ Sell | Open Market | 2,308 | $20K | 4/11/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 817 | $7K | 4/10/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 17,155 | $148K | 3/7/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 88,652 | $0 | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 6,529 | $56K | 3/6/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,130 | $18K | 1/10/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 995 | $8K | 1/9/2023 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,284 | $16K | 10/10/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 841 | $6K | 10/7/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,300 | $24K | 7/8/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 825 | $8K | 7/7/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 831 | $11K | 4/7/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,244 | $15K | 3/7/2022 | View on chart |
| ADPT | ▲ Buy | Grant | 74,135 | $0 | 3/4/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,021 | $24K | 1/7/2022 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,801 | $61K | 10/8/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,324 | $43K | 10/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.